AIT Worldwide set to buy UK pharma forwarder Mach II Shipping
Fast-growing US 3PL AIT Worldwide is set to further expand in Europe with the purchase ...
It has become increasingly obvious to most people since the onset of the pandemic that there is little chance of any society returning to “normal” without the development of some sort of coronavirus vaccine. And anyone cognisant of how supply chains work will understand that it is one thing developing a vaccine, and quite a different thing to get it to those who will need it – a number expected to ultimately amount to hundreds of millions, if not billions, of people. This op-ed in European Pharmaceutical Review looks at some of the challenges logistics operators and pharmaceutical shippers are likely to face: “It is very likely that demand for the vaccine will outstrip supply, at least in the immediate term. It will therefore be vital to identify the most vulnerable segments of the population, ensuring that they receive the vaccine as a priority. In addition to supplying the actual vaccine, syringes, needles and peripherals also need to be taken into consideration when planning the supply chain. These are often delivered by different parties, but are just as important as the vaccine itself and must be supplied in abundance so the dose can be administered safely.”
Etail by air – here to stay or on a short shelf life?
HMM sees opportunities in Hapag-Lloyd’s exit from THE Alliance
How crazy is this: DSV goes hostile on Expeditors or CH Robinson?
Liners unveil Asia-Europe FAK price hikes to arrest steady rate decline
Legal battle heats up over 'unseaworthy' and 'reckless' MV Dali
Increasing scrutiny could stall rise of ecommerce platforms, as TikTok faces US ban
Another strong month for US ports as container flows continue to rise
Alex Lennane
email: [email protected]
mobile: +44 7879 334 389
During August 2023, please contact
Alex Whiteman
email: [email protected]
Alessandro Pasetti
email: [email protected]
mobile: +44 7402 255 512
Comment on this article